

## FLORIDA PDMP REPORTING FOR CLINICAL TRIALS

If the clinical trial drug contains a controlled substance in schedule II, III, or IV, as defined in section 893.03, F.S., it **MUST** be reported to the PDMP. If the clinical trial contains a controlled substance as defined by federal law, but that drug is not scheduled in section 893.03, F.S., then it does not have to be reported.

With regard to double blind clinical trials, as long as it is an FDA/DEA-approved trial, it is not necessary to report, as the dispensing practitioner would not know whether or not he or she has dispensed a controlled substance.